Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.52 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10192033 | 0.91 | ALDH1A1 (0.61) | KMT2ASMN1; SMN2MEN1ALDH1A1HTT | |
| SCHEMBL3786216 | 0.87 | SMN1; SMN2 (0.71) | KMT2ASMN1; SMN2MEN1ATMALDH1A1 | |
| SCHEMBL12407138 | 0.85 | SMN1; SMN2 (0.73) | KMT2ASMN1; SMN2MEN1ALDH1A1HTT | |
| SCHEMBL15167068 | 0.85 | ALDH1A1 (0.54) | KMT2ASMN1; SMN2MEN1ALDH1A1HTT | |
| SCHEMBL95577 | 0.83 | ALDH1A1 (0.53) | KMT2ASMN1; SMN2MEN1ALDH1A1HTT | |
| SCHEMBL10192034 | 0.83 | FAAH (0.67) | KMT2ASMN1; SMN2MEN1ALDH1A1HTT | |
| SCHEMBL10192032 | 0.83 | KMT2A (0.54) | KMT2ASMN1; SMN2MEN1ALDH1A1HTT | |
| SCHEMBL10708813 | 0.83 | GAA (0.55) | KMT2ASMN1; SMN2MEN1ALDH1A1HTT | |
| SCHEMBL97442 | 0.83 | GAA (0.51) | KMT2ASMN1; SMN2MEN1ATMALDH1A1 | |
| SCHEMBL8065643 | 0.83 | ALDH1A1 (0.70) | KMT2ASMN1; SMN2MEN1ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | KMT2A 3974/4885SMN1; SMN2 4525/4885MEN1 4815/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | KMT2A 4464/4885SMN1; SMN2 3609/4885MEN1 4800/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | KMT2A 4464/4885SMN1; SMN2 3609/4885MEN1 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.